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Abstract
Background: Diabetic Retinopathy is one of the most common causes of blindness among adults. Microvascular
complications may have common origins. The objective of the present study is to analyze the correlation between
urinary IgM excretion and diabetic retinopathy based on the type of diabetes.
Methods: The present study is cross-sectional analytic and was carried out on 140 type2 diabetic patients (of which
70 patients diagnosed with retinopathy) and 76 type1 diabetic patients (of which 37 patients diagnosed with
retinopathy). For every patient in each of the test groups, fasting plasma glucose, triglyceride, cholesterol, creatinin
and HbA1c tests were done. The value of IgM, the albumin- to- creatinine ratio and the urine analysis test were also
used to rule out the significant proteinuria of the patients. Then, IgM Index was measured using the following
equation: Igm Index = Urine IgM/Urine Cr.
Results: The level of IgM index in the diabetic patients (type1 and type2) had no significant correlation with
retinopathy. Cut point = 1.49, sensitivity = 0.703 and specificity = 0.308 in type1 diabetes were used for screen
retinopathy. In type1 diabetic patients, the duration of diabetes had a significant correlation with urinary protein
while in type 2 diabetic patients, the diabetes duration and HbA1c were significantly correlated with retinopathy.
Conclusion: The results of this study demonstrate that the level of urinary IgM in diabetic patients has no
difference in those who have or lack retinopathy, but the urinary IgM level of more than 1.49 mg/dl can be
considered as a cut point in type1 diabetic patients to screen retinopathy.
Keywords: Diabetes Complications, Diabetic Retinopathy, Urinary IgM
Background
Diabetes mellitus includes a group of common metabolic
disorders among which the distinguishing characteristic
is phenotypic hyperglycemia. The global incidence of
diabetes mellitus increased from 30 million cases in
1985 to 285 million in 2010. In Kerman- Iran, the stan-
dardized prevalence of diabetes was 9 % (men 7.7 % and
women 10.3 %) [1]. Moreover, in Iran as a developing
country, about 6 % of the population suffers from type2
diabetes and its complications. As a result, the morbidity
and mortality of this disease is also increasing [2, 3].
Diabetic retinopathy is one of the microvascular
complications of diabetes and is also one of the most
common reasons for blindness among 20 to 74 year-old
adults [4, 5]. The type and duration of diabetes, age, sex,
glycemic control, systemic hypertension,body mass index,
smoking, and serum lipid and microalbuminuria are all as-
sociated with the progress of diabetic retinopathy [6–10].
Microalbuminuria is significantly correlated with dia-
betic retinopathy in type2 diabetes, and is therefore a re-
liable marker for retinopathy [11]. In type2 patients, the
increase of urinary excretion of albumin is significantly
correlated with retinopathy, neuropathy and cardiovas-
cular diseases [12].
The transfer of proteins from capillary walls of glom-
eruli is done based on the size and electrical load of the
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molecules. One could say that the walls of glomeruli
have the ability of transferring molecules based on the
size and charge of macromolecules [12–14]. In a model
with two pores and one shunt [15], a pore with a small
diameter and radius of 2.9-3.1 nanometers is supposed
for the transfer of negatively charged globular proteins
and a small number of pores with larger radiuses (8–9
nanometers) are supposed for the transition of larger
proteins [16].
In normal conditions, smaller pores are impenetrable
for the transfer of albumin which has a radius of 3.6
nanometers [17]. However, in case there is a lack of a
negative charge, proteins with the radius of 4.5- nano-
meters can pass through such pores [16–18]. Larger pro-
teins with a radius of higher than 5.5 nanometers such
as IgM cannot pass through normal pores and do not
need shunts of glomerular wall [16–18]. Therefore, it
seems that the mechanisms of albumin excretion and
IgM excretion in kidney are different and on the other
hand, it appears that these mechanisms are different in
type1 and type2 diabetes. In patients with type2 diabetes,
urinary IgM excretion is more than patients with type1
diabetes. Moreover, in 86 % of type1 and 35 % of type2
diabetic patients, urinary concentration of IgM was un-
detectable [19]. On the other hand, the association be-
tween vascular complications and diabetes is completely
known. In some studies, the significant correlation be-
tween vascular complications and urinary IgM excretion
has been supported in a way that urinary IgM excretion
increases the possibility of mortality due to cardiovascu-
lar complications and renal disorders in patients with
type1 diabetes without considering the degree of albu-
minuria [20]. It is also observed that in type2 diabetic
nephropathy, the increase of urinary IgM is followed by
mortality due to cardiovascular and renal events [21].
The correlation of urinary IgM excretion with the pro-
gress of renal disorder and mortality of cardiovascular
events has been verified. Though, such correlation has
not been investigated for retinopathy. Micro-vascular
complications might have common origins. Therefore, it
seems that urinary IgM excretion may be significantly
correlated with retinopathy. In the present study, the
objective is to verify the correlation between urinary
IgM excretion and diabetic retinopathy based on the
type of diabetes.
Methods
The present study is cross-sectional and analytical. The
control group included 216 diabetic patients of whom
140 patients had type2 diabetes and 76 patients had
type1 diabetes. Among the 140 type2 patients, 70 had
retinopathy while there were 37 cases of retinopathy
within the 76 patients with type1 diabetes. These pa-
tients were chosen from the visitor of clinical division of
endocrinology in Afzalipur Hospital of Kerman city
(center of a province in southern Iran).
The inclusion criteria were type1 and type2 diabetes.
The diagnosis of diabetes was done based on the stan-
dards of ADA 2014 and confirmed by endocrinologists.
In order to diagnose type1 diabetes, standards of less
than 30 year-old were applied which included acute
onset and diabetic ketoacidosis. If the patients were
older than 30 years, less-than-one level of c-peptide
(c-peptide ≤ 1 ng/ml) was applied as the inclusion criteria
for type1. In the information form the duration of dia-
betes, age, sex, level of glycemic control, blood pressure,
body mass index, smoking and serum lipid levels were
highlighted and adjusted in the statistical calculations.
The exclusion criteria were significant proteinuria
(macro-albuminuria in urine), creatinin > 1.5 mg/dl and
GFR < 90 cc/min per 1.73 m2.
After confirmation through diagnosis and initial in-
spection, the included patients filled the initial forms
and the agreement forms to participate in the study.
They were also given two information papers to visit an
ophthalmologist and get tested at a laboratory. In the la-
boratory, 5 cc (mL) clotted blood of each individual was
sampled to do fasting plasma glucose, triglyceride, chol-
esterol and creatinin tests. 1 cc (mL) of patients’ blood
was also used to do HbA1C tests. All of the mentioned
tests were done through the calorimetric method.
HbA1c was measured through Nycocard/reader П and
Nycocard kit and its normal value was considered to be
less than 6.5 % [4]. In addition, a random sample of
urine was used to measure the value of IgM and
albumin-to-creatinin ratio. Urine analysis test was used
to rule out the patients with significant proteinuria.
Urinary albumin was measured through torbidometeric
method by Perestige system and Randox kit; considering
that the normal value of urinary albumin is less than 20.
Urinary IgM was also measured using the colorimetric
method and by Eliza reader and Bethyl kit. At the
end, the IgM index was calculated using the following
formula [19]:
Igm Index ¼ Urine IgM = Urine Cr
1.8 × 10 -3 was regarded as the cut point of IgM index
for type1 diabetes. Then, all of the patients had eye
examination with open pupils using an ophthalmoscope
done by an ophthalmologist to determine the existence
of retinopathy and its stage.
Finally, the collected data were analyzed through SPSS
Software (version. 21), the tests of analytical and descrip-
tive statistics such as T test X2, regression and linear
multivariate along with univariate tests. Subsequently,
Roc curve was drawn for both groups.
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Results
(Table 1) Based on the information, the mean age in
type1 diabetic patients with retinopathy is more than
those diabetic patients without retinopathy. Also the
mean age in type2 diabetic patients with retinopathy is
more than those without retinopathy. Furthermore, the
gender of patients who suffer or do not suffer from retin-
opathy do not show any difference in the type of diabetes.
The duration of diabetes is longer in type1 diabetic pa-
tients with retinopathy. Likewise, the duration of diabetes
is longer in type 2 diabetic patients with retinopathy. In
individuals who suffer from retinopathy, hypertension is
more common in both types of diabetes with the) p ≤
0.047) in diabetes type1 and (p ≤ 0.003) in diabetes type2.
Mean arterial blood pressure was higher in patients
who suffer from retinopathy. (92/1 ± 9/8 V S 85/6 ± 9/8,
P = 0/0001) One third of patients were receiving antihy-
pertensive medication including losartan (N = 50, 23 %)
enalapril (N = 6), captopril (N = 2), amlodipin (N = 12)
and atenolol (N = 8). Since treatment with antihyperten-
sive might interfere in the interpretation of results related
to Igm, the level of Igm was compared in patients with
and without medication use that less to no significant dif-
ferences. Additionally, in type1 diabetic patients with ret-
inopathy, the mean BMI is significantly higher. However,
this difference is not observed in type2 diabetes.
The results also indicate that smoking is not correlated
with retinopathy in either types of diabetes.
The mean FPG in type2 diabetic patients with retinop-
athy is significantly more than those who lack retinopathy
(162.78 ± 78.6 versus 138.18 ± 64.54) with the p-value of
(0.045). Though, this difference is not observed in type1
diabetes.
The mean HbA1C in type2 diabetic patients with ret-
inopathy is significantly more than those who lack retin-
opathy (8.2 ± 1.69 versus 7.1 ± 1.67) with the p-value of
(0.001). However, this difference is not observed in type1
diabetes.
Neither types of diabetes have significant differences in
their levels of Triglyceride, cholesterol or albumin between
the two groups regardless of having diabetic retinopathy.
The mean urinary protein in type1 diabetic patients
with retinopathy is significantly more than those who
lack retinopathy (22.27 ± 11.42 versus 10.43 ± 10.48) with
the p-value of (0.001), but the same is not the case for
type2 diabetes.
Neither types of diabetes have significant differences in
their IgM index value between the two groups regardless
of having diabetic retinopathy.
(Table 2) Based on univariate linear regression analysis
Table 2, in type1 diabetic patients, the correlation of age,
duration of diabetes, HTN, BMI and urinary protein with
retinopathy is significant. Moreover a significant correl-
ation between retinopathy and sex, smoking, FPG, HbA1c,
Triglyceride, Cholesterol, micro-albuminuria, Urine IgM,
Urine IgM index and urine protein is supported.
Table 1 Shows demographic and laboratory information of diabetic patients with type1 and type 2
Variable DM type I DM type II
Retinopathy Yes, N = 37 Retinopathy No, N = 39 P-value Retinopathy Yes, N = 70 Retinopathy No, N = 70 P-value
Age (year) 34.1 23.6 <0.001 49.8 45.6 <0.001
Sex (female) 17 24 0.170 56 (80 %) 49 (70 %) 0.170
Duration (year) 15.8 7.6 <0.001 12.5 7.0 <0.001
HTN (yes) 9 (24.3 %) 3 (77 %) 0.047 36 (51.4) 19 (27 %) 0.003
Mean arterial BP 81/9 ± 8/0 87/5 ± 8/4 0/004 91/6 ± 15/7 90/7 ± 10/3 p = 0/6
Systolic BP (mm Hg) 110/6 ± 11/98 119/3 ± 15/5 <0/05 118/6 ± 14/6 133/109 ± 1/8 P = 0/0001
Diastolic BP (mm Hg) 67/6 ± 7/1 71/6 ± 6/4 <0/01 72/2 ± 9/1 75/1 + 8/6 P = %6
BMI (kg/m2) 25.1 22.5 0.015 30.0 29.8 0.773
Cigarette (yes) 6 (16.2 %) 2 (5.1 %) 0.148 9 (12.9 %) 2 (2.9 %) 0.028
FPG (mg/dl) 162.4 172.7 0.650 162.7 138.18 0.045
HbA1c% 7.7 7.7 0.920 8.2 7.1 <0.001
TRIGLYCERIDE (mg/dl) 154.5 133.3 0.287 190.2 193.4 0.870
Cholesterol (mg/dl) 191.6 173.0 0.068 186.0 184.5 0.784
Urine Albumin (mg/dl) 30.5 20.3 0.074 30.6 20.3 0.063
Urine Creatinine (mg/dl) 198.5 141.0 0.132 137.3 223.9 <0.001
Urine protein (mg/l) 222.7 104.3 <0.001 15.4 15.4 0.900
IgM (mg/dl) 0.114 0.096 0.530 0.191 0.044 0.167
IgM Index 6.2 4.1 0.192 15.6 12.7 0.565
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The results of this test indicate that there is no signifi-
cant correlation between retinopathy and measured fac-
tors such as age, duration of diabetes, HTN, smoking,
FPG, HbA1c and Creatinin in type2 diabetic patients.
The same is the case for the relationship between sex,
BMI, cholesterol, Triglyceride, micro-albuminuria, urine
protein and IgM index in this type of patients.
In univariate test of type1 diabetes, it is observed that
age, duration of diabetes, hypertension, BMI and urine
protein are associated with diabetic retinopathy. Vari-
ables with P < 0.2 are verified by multivariate test to de-
termine any independent correlation with retinopathy.
In multivariate test, no correlation is found between
IgM index and retinopathy even after the exclusion of
other variables, but a significant correlation between ret-
inopathy and the duration of diabetes and urine protein
is observed.
In the univariate test of type2 diabetes, it is observed
that variables of ages, diabetes duration, hypertension,
smoking, and FPG, HbA1c and urine creatinin are sig-
nificantly correlated with retinopathy. The variables of
P-value <0.2 are analyzed in multivariate test to verify
their independent correlation with retinopathy. When
other variables are excluded, the IgM index has no rela-
tionship with retinopathy while variables such as duration
of diabetes and HbA1c are independently correlated with
retinopathy (Table 3, Fig. 1, Fig. 2).
Based on Roc curve for type1 diabetes, multiple cut
points were determined. Considering that the objective of
this study was to set a criterion for screening retinopathy,
and high sensitivity is desired for screening, 1.49 × 10−3,
0.703 and 0.308 values were defined as cut point, sensitiv-
ity and specificity respectively. Regarding type2 diabetes,
determination of cut point was impossible.
Discussion
The present study showed that the mean urinary IgM
was not different between the diabetic patients with or
without retinopathy, but the urinary IgM level of higher
than 1.49 × 10−3 mg/dl could be used as a cut point for
type1 diabetic patients to predict retinopathy. This study
also supports the correlation of diabetes duration and
urine protein with retinopathy in type1 diabetes as sup-
ported in previous studies. Besides, the correlation of
Table 2 Correlation of All Variables with IgM in Type I and II Diabetic Patients (Univariate)
Variable DM type I DM type II
OR CI (95 %) P-value OR CI (95 %) P value
Age 1.12 (1.05–1.18) <0.001 1.16 (1.08–1025) 0.001
Sex (Female) 0.53 (0.21–1.32) 0.16 1.71 (0.78–3.7) 0.17
Duration 1.21 (1.10–1.32) 0.001 1.22 (1.12–1.32) 0.001
HTN 3.8 (0.95–15.5) 0.058 2.8 (1.4–5.7) 0.04
BMI 1.14 (1.02–1.27) 0.02 1.012 (0.193–1.09) 0.77
Cigarette 3.5 (0.67–19.00) 0.13 5.01 (1.04–24) 0.044
FPG 0.99 (0.99–1.00) 0.65 1.005 (1–1.01) 0.05
HbA1c 1.01 (0.18–1.26) 0.92 1.49 (1.19–1.86) 0.001
Triglyceride 1.06 (0.33–3.4) 0.91 1.46 (0.72–2.9) 0.28
Cholestrol 1.37 (0.152–3.630) 0.51 1.37 (0.67–2.7) 0.37
Urine Albumin 1.13 (0.198–1.3) 0.078 1.09 (0.99–1.19) 0.07
Urine Creatinine 1.03 (0.999–1.007) 0.16 0.995 (0.992–0.998) 0.001
Microalbuminuria 2.02 (0.74–21.3) 0.16 1.34 (0.68–2.62) 0.39
Urine Protein 7.2 (2.4–21.3) 0.001 1.23 (0.59–2.55) 0.57
IgM Index 1.05 (0.97–1.13) 0.20 1.003 (0.992–1.015) 0.57
IgM 4.6 (0.49–43.2) 0.18 1.72 (0.74–4.01) 0.20
Table 3 Correlation of Variables with IgM in Type I and II
Diabetic Patients (Multivariate)
DM type I DM type II
Variable OR (CI 95 %) P-value OR (CI 95 %) P-value
Age 1.02 (0.99–1.18) 0.08 1.09 (0.99–1.19) 0.061
Sex 0.67 (0.18–2.5) 0.56 1.35 (0.4–4.60) 0.62
Duration 1.18 (1.03–1.35) 0.014 1.13 (1.03–1.23) 0.006
HTN 1.17 (0.11–12.39) 0.89 1.73 (0.68–4.40) 0.24
BMI 0.93 (0.78–1.1) 0.42 5.13 (0.63–31.57) 0.078
Cigarette 0.65 (0.60–7.17) 0.73 0.997 (0.998–1.006) 0.489
Urine Albumin 1.1 (0.20–5.91) 0.91 1.53 (1.02–2.31) 0.038
Urine Creatinin 1.003 (0.99–1.009) 0.28 1.28 (0.51–3.22) 0.59
Urine Protein 7.22 (1.68–30.95) 0.008 0.997 (0.993–1.000) 0.76
IgM Index 1.054 (0.95–1.169) 0.322 0.997 (0.983–1.01) 0.633
Sanjari et al. Journal of Diabetes & Metabolic Disorders  (2016) 15:18 Page 4 of 7
diabetes duration and HbA1c with retinopathy was sup-
ported in the type2 diabetes group.
The idea of the correlation between urinary IgM and
renal complications was raised long ago. In a work by
Bakoush et.al [19], they found that urinary IgM excre-
tion in type2 diabetic retinopathy is more than type1
diabetic retinopathy. Later, Bakoush et.al [20] did an-
other study on 139 type1 diabetic patients in which they
were analyzed in a follow-up test for the next 18 years.
In this study, 20 patients had final-stage renal disease.
This study showed that patients with different degrees of
albuminuria (i.e. individuals of higher urinary IgM) final
stage of renal disease are three times more common
[20]. In 2012, Bakoush et.al performed a similar study
on type2 diabetes patients and found that of 106 patients
in a follow-up study lasting for five years, 41 individuals
had final-stage renal diseases. During these analyses, it
was observed that the urinary IgM is a proper predictor
for renal involvement without considering the degree of
albuminuria [5]. As far as the analyses of the present study
are concerned, the selected patients had no significant
urinary proteinuria and their values of GFR and Cr were
respectively more than 90 cc (mL) and less than 1.5.
Therefore, due to the limitations in the selection of pa-
tients, the investigation of the correlation between IgM
and nephropathy was impossible.
During the two above-mentioned studies by Bakoush
et.al, the correlation between urinary IgM and cardiovas-
cular events was verified. In patients with type1 diabetes,
the increase of urinary IgM excretion was followed by
the increase of mortality due to cardiovascular events;
without considering the degree of albuminuria [21]. Also,
a significant correlation between micro-albuminuria
and different complications of diabetes was observed.
Micro-albuminuria is a risk factor for cardiovascular
events in type2 diabetes [22] and it was correlated with
type2 diabetes [11].
Due to the fact that vascular complications of diabetes
are linked to each other, the correlation of IgM with
cardiovascular events and end-stage renal disease (ESRD)
was observed in diabetic patients. The analyses of the
present study aimed to investigate the correlation between
Fig. 1 Title: Roc Curve in DM type 1. Legend: (Area under the Curve = 0.716 (CI = 0.629-0.802), P < 0.001)
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urinary IgM and diabetic retinopathy without considering
the degree of albuminuria. The correlation between albu-
minuria and retinopathy was also verified in the present
study. In both types of diabetes, the correlation between
micro-albuminuria and diabetic retinopathy was relatively
significant while this correlation was no more applied
when other variables were ignored and independent cor-
relation among variables was analyzed. This might be due
to the fact that most of the patients in the present study
consumed drugs such as angiotensin-converting enzyme
inhibitor (ACE Inhibitors) or angiotensin receptor blocker
(ARB) to control their blood pressure or albuminuria. This
may be the reason for the reduction of albumin excretion
in these patients. Since mechanisms of urinary IgM and
albumin excretion are different, it does not seem that these
mechanisms might be the confounding factor in urinary
IgM excretion. In order to investigate the correlation be-
tween IgM and nephropathy, a comparison was done be-
tween the urinary IgM and the pre-determined cut point in
Bakoush’s study [19]. However, no significant correlation
was found. Since in that study patients suffered from ad-
vanced stages of renal diseases, a new cut point for type1
diabetes was determined which was 1.49 × 10−3 mg/dl. Sen-
sitivity and specificity were 0.703 and 0.308, respectively.
The limitation of this study was the small sample size
and inability to distinguish between the different degrees
of retinopathy, which was one of its predefined objec-
tives. The present study was cross-sectional but it is bet-
ter to be done in cohort format. In addition, Patients
with advanced types of nephropathy such as those with
significant proteinuria and degrees of renal disorder
were excluded from this study.
Furthermore, It is better to do the future studies in
perspective form with larger samples and based on dif-
ferent degrees of retinopathy. More advanced cases of
nephropathy should also be included along with patients
who have not received treatments for blood pressure
and albuminuria.
Conclusion
The results of the present study demonstrate that in type
2 diabetic patients with and without retinopathy average
values of urinary IgM was not different. However, urinary
IgM level of higher than 1.49x10-3, could be used as a cut
point to predict retinopathy in type1 diabetic patients.
Similar to other studies on this subject, the present study
could show long-term correlation of diabetes and protein-
uria with retinopathy in type1 diabetes. It also could show
the correlation of diabetes duration and HbA1c with ret-
inopathy in type2 diabetes.
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